Atezolizumab
Showing 751 - 765 of 765
Colorectal Cancer Trial in Guangzhou (JS001, regorafenib tablet)
Unknown status
- Colorectal Cancer
- JS001
- regorafenib tablet
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
May 11, 2020
Advanced Non-small Cell Lung Cancer With Malignant Pleural
Unknown status
- Non-Small Cell Lung Cancer
- Non-Intervention
- (no location specified)
Feb 10, 2020
Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction
Completed
- Arthritis
- +7 more
- Immune checkpoint inhibitor
-
Paris, FranceAP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, C
Sep 24, 2019
Lung Tumor Malignant, Interstitial Lung Disease Trial in Warszawa (Prolonged glucocorticosteroid (prednisone) regimen, Short
Unknown status
- Lung Neoplasm Malignant
- Interstitial Lung Disease
- Prolonged glucocorticosteroid (prednisone) regimen
- Short glucocorticosteroid (prednisone) regimen
-
Warszawa, Mazowieckie, PolandInstutut Gruzlicy I Chorob Pluc
Feb 26, 2020
NSCLC Metastatic Trial in Seoul (Pembrolizumab plus chemo, Placebo plus chemo)
Unknown status
- Non-small Cell Lung Cancer Metastatic
- Pembrolizumab plus chemotherapy
- Placebo plus chemotherapy
-
Seoul, Korea, Republic ofJong-Mu Sun
Dec 5, 2019
Inactivated Trivalent Influenza Vaccine on NSCLC Patients
Not yet recruiting
- Non Small Cell Lung Cancer
- Influenza Vaccine
- PD-1/PD-L1 inhibitors
- Inactivated trivalent influenza vaccine
-
Hong Kong, Hong Kong, China
- +1 more
Apr 20, 2020
Testing Tumor Tissue and Blood to Help Select Personalized
Not yet recruiting
- NSCLC
- ctDNA, tumor NGS
- (no location specified)
Mar 2, 2021
Metastatic Colorectal Cancer Trial in Guangzhou (Camrelizumab)
Unknown status
- Metastatic Colorectal Cancer
-
Guangzhou, Guangdong, ChinaCancer center of Sun Yat-sen University
Apr 11, 2019
NSCLC Trial in Ann Arbor, Seattle (MPDL3280A, Hypofractionated Radiotherapy)
Completed
- Non-small Cell Lung Cancer
- MPDL3280A
- Hypofractionated Radiotherapy
-
Ann Arbor, Michigan
- +1 more
Feb 7, 2019
The Predicted Potential of Quantitative T Cell Repertoire(TCR)
Unknown status
- Non-Small Cell Lung Cancer
- Atezolizumab (MPDL3280A)
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital of College of Medicine, Zhejiang U
Jul 21, 2017
Advanced or Metastatic Melanoma, Advanced or Metastatic NSCLC Trial in France (immune-checkpoint inhibitors therapies)
Unknown status
- Advanced or Metastatic Melanoma
- Advanced or Metastatic NSCLC
- immune-checkpoint inhibitors therapies
-
Marseille, Bouches Du Rhône, France
- +8 more
Sep 25, 2019
Tumor, Solid, Lymphoma Trial in Beijing (GR1405 injection)
Unknown status
- Tumor, Solid
- Lymphoma
- GR1405 injection
-
Beijing, ChinaCancer Institute/Hospital, Chinese Academy of Medical Sciences &
Nov 4, 2018
Urothelial Carcinoma Trial in United States (Atezolizumab [TECENTRIQ])
Approved for marketing
- Urothelial Carcinoma
- Atezolizumab [TECENTRIQ]
-
Scottsdale, Arizona
- +39 more
Nov 1, 2016
Cancer, Multiple Indications Trial in United States (Anti-PDL-1 antibody)
Completed
- Cancer, Multiple Indications
- Anti-PDL-1 antibody
-
Los Angeles, California
- +10 more
Sep 3, 2015